@entity432 through a XXXX : treatment for @entity157 .

@entity1 @entity632 @entity63 @entity2617 @entity1184 @entity5 @entity797 @entity432 @entity157 @entity99
PURPOSE: To evaluate the therapeutic efficacy and safety of supplemental transcatheter arterial chemoembolization (TACE) through the extrahepatic @entity432 ( @entity432 ) for the treatment of @entity157 ( @entity157 ). METHODS: We studied 21 @entity1 with extrahepatic collaterals of the @entity432 , among 1,512 @entity1 with @entity157 who had undergone angiography. HCCs supplied by collateral OAs were located at: segment IV in seven, segment V in five, segment III in three, segment VI in three and segment @entity797 in three @entity1 (Couinaud classification of segments). On preoperative CT scans, every @entity157 was abutting the liver surface. @entity2617 or engorgement was noted in 11 @entity1 . @entity99 showed @entity1184 of the feeding @entity432 in all @entity1 . TACE of the @entity432 was performed in 19 @entity1 with an emulsion of iodized oil and @entity632 . Embolization with gelatin sponge particles was added in five @entity1 . RESULTS: Collaterals of the @entity432 to the @entity157 were found on the first to seventeenth sessions of TACE. On follow-up CT scans, five @entity1 showed complete uptake of iodized oil in the @entity5 . Partial uptake of iodized oil was noted in 13 @entity1 and no uptake in one @entity1 . There was no serious complication that related to the omental embolization, such as @entity63 . The cumulative survival rates from the time of the TACE of the @entity432 were 81% at 6 months and 68% at 12 months. CONCLUSION: TACE of the @entity432 is safe and has a potential therapeutic effect in the treatment of @entity157 .
